Andrew W
2021-03-25 13:38:46 UTC
https://www.afinalwarning.com/505746.html
Researchers in two countries have confirmed the mechanism by which
AstraZeneca's Wuhan coronavirus (COVID-19) vaccine could cause harmful
side-effects. The findings come as a number of countries temporarily halted
the use of the jab in their immunization campaigns following reports of
blood clots. Nevertheless, health authorities have insisted on the jab's
safety and remarked that vaccinations ought to continue. Researchers at
northern Germany's Greifswald University Hospital said on March 19 that they
discovered how the AstraZeneca jab could cause blood clots and brain
thrombosis. The team, led by Andreas Greinacher, said in a statement that
the British drug manufacturer's vaccine may prompt over-activation of blood
platelets or thrombocytes in some cases. Excessive thrombocyte activity can
lead to the formation of clots in blood vessels, blocking regular blood
flow.
Antibodies caused blood clots
The researchers found that antibodies stimulated by AstraZeneca's vaccine
trigger platelets to coagulate, in the same manner as when wounds heal. They
continued that the vaccination activated a mechanism that caused these clots
to form in the brains of some patients. According to a March 21 NPR report,
Greinacher and his team looked at 13 cases of cerebral blood clots that
occurred in Germany within four to 16 days after receiving the AstraZeneca
vaccine. Out of the 13 cases, 12 of them were female and almost all affected
were below 55 years old. The team managed to isolate and identify the
specific antibodies that caused the platelets to become over-active.
Meanwhile, researchers in Norway led by Oslo University Hospital Chief
Physician Dr. Pål André Holme conducted a probe of three post-vaccination
blood clot cases reported in the country. The three cases occurred in
healthcare workers below 50 years old. Speaking to the Norwegian newspaper
VG, the chief physician said he is confident that his team had identified
antibodies responsible for the blood clots that were triggered by the
vaccination. "Our theory is that this is a strong immune response that most
likely comes after the vaccine," Holme said. He added that "there is no
other thing than the vaccine that can explain this immune response." Holme
further explained: "I'm pretty sure it's the antibodies that's the cause [of
the clotting], and I see no other reason than that it's the vaccine that
causes it."
Health authorities still believe AstraZeneca jab is safe
Despite Greinacher and Holme's findings, health authorities in Europe have
yet to be persuaded to halt the use of the vaccine. The European Medicines
Agency (EMA) said in a March 19 statement that the benefits of getting the
AstraZeneca vaccine "still outweigh the risks." (Related: EU IN CRISIS:
Deadly rollout of AstraZeneca vaccine destroys EU's reputation, shatters
image of unity within bloc.) The statement also outlined the findings of
EMA's Pharmacovigilance Risk Assessment Committee during its extraordinary
meeting held on March 18. The committee concluded that the vaccine's
benefits outweighing its purported risks and that it lacked an association
with an increase in blood clots for those who got it. Furthermore, it
confirmed that there is no evidence of a problem "related to specific
batches of the vaccine or to particular manufacturing sites." Three days
before the European regulator released its findings, EMA Executive Director
Emer Cooke defended the AstraZeneca jab. She commented that "there is no
indication that vaccination has caused these [serious] conditions" during a
March 16 press conference. "A situation like this is not unexpected when you
vaccinate millions of people," Cooke continued. The World Health
Organization (WHO) also defended the safety of AstraZeneca's vaccine. During
a March 15 press conference, WHO Director General Tedros Adhanom Ghebreyesus
said that the global health body "is in close contact with the [EMA]" and
has been "reviewing the available [safety] data" of the jab. "This does not
necessarily mean these [adverse] events are linked to the vaccine, but it's
routine practice to investigate them – and it shows that the [vaccine]
surveillance system works and effective controls are in place," he said.
During the same press conference, WHO Chief Scientist Soumya Swaminathan
commented that it is best for countries to continue inoculation using the
AstraZeneca vaccine. "We do not want people to panic and we would, for the
time being, recommend that countries continue vaccinating with AstraZeneca,"
she said. (Related: 20+ countries suspend use of AstraZeneca vaccine, but
regulators insist 'benefits outweigh risks'.) The chief scientist added that
some incidents of blood clotting in the general population were to be
expected. "So far, we do not find an association between these events and
the vaccine. [This is] because the rates at which these events have occurred
in the vaccinated group are … less than what you would expect in the general
population," Swaminathan explained.
Researchers in two countries have confirmed the mechanism by which
AstraZeneca's Wuhan coronavirus (COVID-19) vaccine could cause harmful
side-effects. The findings come as a number of countries temporarily halted
the use of the jab in their immunization campaigns following reports of
blood clots. Nevertheless, health authorities have insisted on the jab's
safety and remarked that vaccinations ought to continue. Researchers at
northern Germany's Greifswald University Hospital said on March 19 that they
discovered how the AstraZeneca jab could cause blood clots and brain
thrombosis. The team, led by Andreas Greinacher, said in a statement that
the British drug manufacturer's vaccine may prompt over-activation of blood
platelets or thrombocytes in some cases. Excessive thrombocyte activity can
lead to the formation of clots in blood vessels, blocking regular blood
flow.
Antibodies caused blood clots
The researchers found that antibodies stimulated by AstraZeneca's vaccine
trigger platelets to coagulate, in the same manner as when wounds heal. They
continued that the vaccination activated a mechanism that caused these clots
to form in the brains of some patients. According to a March 21 NPR report,
Greinacher and his team looked at 13 cases of cerebral blood clots that
occurred in Germany within four to 16 days after receiving the AstraZeneca
vaccine. Out of the 13 cases, 12 of them were female and almost all affected
were below 55 years old. The team managed to isolate and identify the
specific antibodies that caused the platelets to become over-active.
Meanwhile, researchers in Norway led by Oslo University Hospital Chief
Physician Dr. Pål André Holme conducted a probe of three post-vaccination
blood clot cases reported in the country. The three cases occurred in
healthcare workers below 50 years old. Speaking to the Norwegian newspaper
VG, the chief physician said he is confident that his team had identified
antibodies responsible for the blood clots that were triggered by the
vaccination. "Our theory is that this is a strong immune response that most
likely comes after the vaccine," Holme said. He added that "there is no
other thing than the vaccine that can explain this immune response." Holme
further explained: "I'm pretty sure it's the antibodies that's the cause [of
the clotting], and I see no other reason than that it's the vaccine that
causes it."
Health authorities still believe AstraZeneca jab is safe
Despite Greinacher and Holme's findings, health authorities in Europe have
yet to be persuaded to halt the use of the vaccine. The European Medicines
Agency (EMA) said in a March 19 statement that the benefits of getting the
AstraZeneca vaccine "still outweigh the risks." (Related: EU IN CRISIS:
Deadly rollout of AstraZeneca vaccine destroys EU's reputation, shatters
image of unity within bloc.) The statement also outlined the findings of
EMA's Pharmacovigilance Risk Assessment Committee during its extraordinary
meeting held on March 18. The committee concluded that the vaccine's
benefits outweighing its purported risks and that it lacked an association
with an increase in blood clots for those who got it. Furthermore, it
confirmed that there is no evidence of a problem "related to specific
batches of the vaccine or to particular manufacturing sites." Three days
before the European regulator released its findings, EMA Executive Director
Emer Cooke defended the AstraZeneca jab. She commented that "there is no
indication that vaccination has caused these [serious] conditions" during a
March 16 press conference. "A situation like this is not unexpected when you
vaccinate millions of people," Cooke continued. The World Health
Organization (WHO) also defended the safety of AstraZeneca's vaccine. During
a March 15 press conference, WHO Director General Tedros Adhanom Ghebreyesus
said that the global health body "is in close contact with the [EMA]" and
has been "reviewing the available [safety] data" of the jab. "This does not
necessarily mean these [adverse] events are linked to the vaccine, but it's
routine practice to investigate them – and it shows that the [vaccine]
surveillance system works and effective controls are in place," he said.
During the same press conference, WHO Chief Scientist Soumya Swaminathan
commented that it is best for countries to continue inoculation using the
AstraZeneca vaccine. "We do not want people to panic and we would, for the
time being, recommend that countries continue vaccinating with AstraZeneca,"
she said. (Related: 20+ countries suspend use of AstraZeneca vaccine, but
regulators insist 'benefits outweigh risks'.) The chief scientist added that
some incidents of blood clotting in the general population were to be
expected. "So far, we do not find an association between these events and
the vaccine. [This is] because the rates at which these events have occurred
in the vaccinated group are … less than what you would expect in the general
population," Swaminathan explained.